Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma

Leuk Lymphoma. 2022 Sep;63(9):2233-2237. doi: 10.1080/10428194.2022.2068002. Epub 2022 May 9.

Affiliations

¹ Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Dermatopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Dexamethasone / therapeutic use
Exanthema* / drug therapy
Exanthema* / etiology
Humans
Lenalidomide / adverse effects
Multiple Myeloma* / complications
Multiple Myeloma* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
dupilumab
Dexamethasone
Lenalidomide

Grants and funding